About this Research Topic
Irritable Bowel Syndrome (IBS) presents a significant clinical challenge due to its complex pathophysiology and diverse symptoms. Pharmacotherapy remains a cornerstone in managing IBS, with ongoing advancements shaping treatment paradigms. By examining emerging treatments and therapeutic approaches, this Research Topic aims to address the evolving landscape of IBS management. Our primary goal is to provide healthcare professionals, researchers, and stakeholders with insights into cutting-edge pharmacotherapy options for IBS by exploring novel pharmacological agents, therapeutic targets, and innovative strategies aimed at improving symptom control, enhancing treatment efficacy, and minimizing adverse effects in patients with IBS.
In this Research Topic, we welcome articles that investigate the efficacy and safety of both traditional and novel pharmacological interventions for IBS, including but not limited to medications targeting visceral hypersensitivity, gut motility, and inflammation. We encourage submissions that explore the mechanistic underpinnings of emerging therapies, evaluate their clinical utility through well-designed clinical trials, and discuss their potential impact on patient outcomes and quality of life. Additionally, we invite contributions that examine the role of personalized medicine approaches, such as pharmacogenomics and microbiome-based therapies, in tailoring treatment strategies for individual patients with IBS. Through this comprehensive exploration of pharmacotherapy for IBS, we aim to foster a deeper understanding of the disease mechanisms and facilitate the translation of scientific discoveries into effective clinical management strategies.
We welcome a variety of article types, including under the following categories: Original Research, Review, Mini Review, Brief Research Report, and Perspective.
In this Research Topic, we welcome articles that investigate the efficacy and safety of both traditional and novel pharmacological interventions for IBS, including but not limited to medications targeting visceral hypersensitivity, gut motility, and inflammation. We encourage submissions that explore the mechanistic underpinnings of emerging therapies, evaluate their clinical utility through well-designed clinical trials, and discuss their potential impact on patient outcomes and quality of life. Additionally, we invite contributions that examine the role of personalized medicine approaches, such as pharmacogenomics and microbiome-based therapies, in tailoring treatment strategies for individual patients with IBS. Through this comprehensive exploration of pharmacotherapy for IBS, we aim to foster a deeper understanding of the disease mechanisms and facilitate the translation of scientific discoveries into effective clinical management strategies.
We welcome a variety of article types, including under the following categories: Original Research, Review, Mini Review, Brief Research Report, and Perspective.
Keywords: IBS, Irritable Bowel Syndrome, Visceral Hypersensitivity, Functional Gastrointestinal Disorders, Gut Microbiome, Gut Motility, Pharmacotherapy of IBS
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
